Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic Syndromes
Thrombocytopenia

First Posted Date: 2004-04-27

Last Posted Date: 2013-06-26

Lead Sponsor: Drexel University College of Medicine

Registration Number: NCT00003619

Locations: 🇺🇸
Medical College of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Medical College of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2004-04-08

Last Posted Date: 2012-03-08

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 20

Registration Number: NCT00080925

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Not Applicable

Completed

Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Childhood Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Childhood Renal Cell Carcinoma
Chronic Phase Chronic Myelogenous Leukemia
Clear Cell Renal Cell Carcinoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Adult Acute Myeloid Leukemia With Del(5q)

Interventions: Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: allogeneic bone marrow transplantation
Procedure: peripheral blood stem cell transplantation
Biological: therapeutic allogeneic lymphocytes
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2004-04-02

Last Posted Date: 2019-09-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 55

Registration Number: NCT00005799

Locations: 🇩🇪
Universitaet Leipzig, Leipzig, Germany
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States

and more 4 locations

Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2004-03-25

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00008151

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Small Lymphocytic Lymphoma

Interventions: Drug: romidepsin
Biological: rituximab
Drug: fludarabine phosphate
Other: laboratory biomarker analysis

First Posted Date: 2004-03-10

Last Posted Date: 2013-07-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00079443

Locations: 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2004-03-10

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00079144

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Childhood Myelodysplastic Syndromes
Childhood Nasal Type Extranodal NK/T-cell Lymphoma
Chronic Myelomonocytic Leukemia
Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma

Interventions: Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: laboratory biomarker analysis

First Posted Date: 2004-03-09

Last Posted Date: 2020-01-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 37

Registration Number: NCT00078858

Locations: 🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States
🇺🇸
Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

and more 7 locations

Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery

Phase 1

Withdrawn

Conditions: Kidney Cancer
Breast Cancer
Testicular Germ Cell Tumor
Melanoma (Skin)
Lung Cancer

First Posted Date: 2004-03-08

Last Posted Date: 2015-11-13

Lead Sponsor: Northwestern University

Registration Number: NCT00006126

Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2004-02-25

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 31

Registration Number: NCT00005593

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Cleveland, Ohio, United States

Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: fludarabine phosphate
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-02-16

Last Posted Date: 2014-03-07

Lead Sponsor: University of Chicago

Target Recruit Count: 16

Registration Number: NCT00004145

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy